NX Development Corp | Finanzwire

Basculer en Français

9527	Companies
187417	Keywords
119452	Articles
100180	Press releases

Home
Companies
NX Development Corp

BRIEF

published on 06/21/2024 at 15:05, 1 year 5 months ago

NX Development Corp. Enrolls First Patient in OVA-302 Study After FDA Orphan Designation for Gleolan(R)

Gleolan NX Development Corp. OVA-302 Study FDA Orphan Designation
PRESS RELEASE

published on 06/21/2024 at 15:00, 1 year 5 months ago

NX Development Corp. Enrolls First Patient in OVA-302 Study After FDA Orphan Designation for Gleolan(R)
NX Development Corp. enrolls first patient in OVA-302 study for cancer management using Gleolan following FDA's Orphan Designation. CEO DeSena and Chairman Kosciessa express excitement for future programs

Gleolan NX Development Corp. OVA-302 Study Cancer Management Flourescence-guided Surgery
BRIEF

published on 03/05/2024 at 23:05, 1 year 9 months ago

NX Development Corp. Awarded Orphan-Drug Designation for Gleolan in Ovarian Cancer Treatment

FDA NX Development Corp Orphan-Drug Designation Gleolan Ovarian Cancer
PRESS RELEASE

published on 03/05/2024 at 23:00, 1 year 9 months ago

NX Development Corp. is Granted Orphan-Drug Designation Status by US FDA for Gleolan(R) in Ovarian and Related Cancers
NX Development Corp. has achieved orphan-drug status from the FDA for Gleolan, aiding in the visualization of ovarian tumors during surgery. The milestone highlights innovation in cancer care and surgery

FDA Cancer Care Gleolan NX Development Corp. Orphan-drug Status

Accesswire

Published on 12/15/2025 at 16:35, 32 minutes ago

Stillwater Critical Minerals Announces Upsize of Bought Deal LIFE Private Placement for Gross Proceeds of C$15 Million
Published on 12/15/2025 at 15:00, 2 hours 7 minutes ago

Kingfisher Reports Annual General Meeting Voting Results
Published on 12/15/2025 at 15:00, 2 hours 7 minutes ago

Jaguar Health Announces Abstract Submission for Preliminary Data from US Investigator-Initiated Trial of Crofelemer in Adult Patients with Short Bowel Syndrome with Intestinal Failure (SBS-IF)
Published on 12/15/2025 at 14:30, 2 hours 37 minutes ago

Unusual Machines Congratulates Customers Selected for the Army's PBAS Tranche 1.1, Including Envision Technology and Strategic Logix
Published on 12/15/2025 at 14:00, 3 hours 7 minutes ago

Dateline Delivers Further High-Grade Intercepts from North Pipe at Colosseum

View all ACCESSWIRE

EQS Group

Published on 12/15/2025 at 16:42, 24 minutes ago

EQS-Adhoc: Vitruvia Medical AG: successfull capital increase and strengthening of the financial structure
Published on 12/15/2025 at 16:08, 59 minutes ago

Conversion of The Platform Group AG into a KGaA completed as planned
Published on 12/15/2025 at 15:50, 1 hour 16 minutes ago

Original-Research: Cabka N.V. (von First Berlin Equity Research GmbH): Kaufen
Published on 12/15/2025 at 15:49, 1 hour 17 minutes ago

Mutares submits an irrevocable offer to acquire Venator Ultramarine Blue Pigments business from Venator France SAS
Published on 12/15/2025 at 15:45, 1 hour 21 minutes ago

Form 8.3 - The Vanguard Group, Inc.: Qualcomm Incorporated

Les Echos

Published on 12/15/2025 at 11:50, 5 hours 16 minutes ago

Statement about the number of shares composing the share capital and the number of voting rights as of November 30, 2025
Published on 12/12/2025 at 18:00, 2 days 23 hours ago

Disclosure of trading in own shares between November 24th and November 28th, 2025
Published on 12/12/2025 at 09:15, 3 days 7 hours ago

CHANGE IN THE SHARE CAPITAL
Published on 12/11/2025 at 19:23, 3 days 21 hours ago

Eiffage is joining the CAC 40 index
Published on 12/11/2025 at 08:30, 4 days 8 hours ago

Edenred and Daimler Truck join forces to accelerate the rollout of charging infrastructure for electric trucks in Europe

View all LES ECHOS COMFI WIRE